[PDF][PDF] Tofacitinib in combination with conventional disease‐modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient‐reported outcomes from …
V Strand, JM Kremer, D Gruben… - Arthritis care & …, 2017 - Wiley Online Library
Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis
(RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with …
(RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with …
Long-term chikungunya sequelae in Curaçao: burden, determinants, and a novel classification tool
J Elsinga, I Gerstenbluth… - The Journal of …, 2017 - academic.oup.com
Background Beyond the acute illness phase, chikungunya constitutes a public health
problem given its chronic disease phase, which may include long-term arthralgia, arthritis …
problem given its chronic disease phase, which may include long-term arthralgia, arthritis …
Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis
V Strand, RF van Vollenhoven, EB Lee… - …, 2016 - academic.oup.com
Objective. To evaluate effects of tofacitinib or adalimumab on patient-reported outcomes
(PROs) in patients with moderate to severe RA and inadequate responses to MTX. Methods …
(PROs) in patients with moderate to severe RA and inadequate responses to MTX. Methods …
Patient expectations and perceptions of goal-setting strategies for disease management in rheumatoid arthritis
V Strand, GC Wright, MJ Bergman, J Tambiah… - The Journal of …, 2015 - jrheum.org
Objective. To identify how patients perceive the broad effect of active rheumatoid arthritis
(RA) on their daily lives and indicate how RA disease management could benefit from the …
(RA) on their daily lives and indicate how RA disease management could benefit from the …
[HTML][HTML] Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
M Schiff, T Takeuchi, R Fleischmann, CL Gaich… - Arthritis Research & …, 2017 - Springer
Background This study evaluates patient-reported outcomes (PROs) in a double-blind,
phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in …
phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in …
A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to …
P Mease, V Strand, L Shalamberidze, A Dimic… - Annals of the …, 2012 - ard.bmj.com
Background Interleukin 6 (IL-6) plays a key role in the inflammatory cascade in rheumatoid
arthritis. BMS945429 is a humanised, monoclonal antibody that potently binds IL-6 …
arthritis. BMS945429 is a humanised, monoclonal antibody that potently binds IL-6 …
[HTML][HTML] Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate …
V Strand, J Kremer, G Wallenstein, KS Kanik… - Arthritis research & …, 2015 - Springer
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid
arthritis. Method In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients …
arthritis. Method In this 6-month, phase 3, randomized, placebo-controlled trial, 611 patients …
[HTML][HTML] Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and …
V Strand, M Schiff, N Tundia, A Friedman… - Arthritis Research & …, 2019 - Springer
Abstract Background Patient-reported outcomes (PROs) are important when evaluating
treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective …
treatment benefits in rheumatoid arthritis (RA). We compared upadacitinib, an oral, selective …
Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
Objectives To compare patient-reported outcomes (PROs) in methotrexate (MTX)-naive
patients (defined as no prior treatment or≤ 3 doses) receiving tofacitinib versus MTX …
patients (defined as no prior treatment or≤ 3 doses) receiving tofacitinib versus MTX …
TNF as a target of inflammation in rheumatoid arthritis
H Yamanaka - Endocrine, Metabolic & Immune Disorders-Drug …, 2015 - ingentaconnect.com
Anti-Tumor Necrosis Factor (TNF) agents were the first molecular targeting drugs developed
for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of …
for the treatment of rheumatoid arthritis (RA). Anti-TNF agents improve the clinical picture of …